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solving, targets correctional physicians,
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and case managers. Published monthly and
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up-to-the moment information on HIV/AIDS,
hepatitis, and other infectious diseases,
as well as efficient ways to administer
treatment in the correctional environment.
Continuing Medical Education credits are
provided by Medical Education Collaborative
(MEC). This activity is jointly sponsored by
IDCR and Medical Education Collaborative
(MEC). IDCR is distributed to all members of
the Society of Correctional Physicians (SCP)
within the SCP publication, CorrDocs
(www.corrdocs.org).
IDCR and AAHIVM have united to improve
the quality of health care delivery in the
nation's correctional facilities by leveraging
the knowledge, experience and resources of
two diverse and accomplished groups of HIV
and correctional health care experts.
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Introduction
Antiretroviral therapy (ART) has revolutionized
the management of HIV infection. A recent
analysis estimates that currently available combination ART regimens have increased the life
expectancy of HIV-infected individuals by
approximately 24 years.1 The limitations of ART
are plain to HIV clinicians and their patients.
Although generally well tolerated, ART can be
complicated by immediate and chronic adverse
effects. Further, therapy is expensive and must
be taken for years, if not for life. The astoundingly rapid ability of HIV to replicate and produce functional but mutated virus has presented
the greatest challenge to the long-term control
of the infection. In corrections, where HIV-infected inmates may pass in and out of prison and
jails and have intermittent exposure to ART, HIV
drug resistance is not uncommon. For correctional health providers managing HIV infection,
an understanding of HIV drug resistance is
essential. Below are some of the most commonly asked questions regarding ART resistance.
How common is drug resistance?
The prevalence of ART drug resistance has
changed over time. Early in the epidemic,
patients treated with zidovudine (AZT) or stavudine (d4T) mono-therapy quickly developed
resistance to these drugs. Likewise, dual nucleoside reverse transcriptase inhibitor (NRTI) regimens used in the early 1990s also led to NRTI
drug resistance, albeit at a slightly slower rate
compared with mono-therapy. With the advent
of protease inhibitors and use of triple combination therapy, profound reductions in HIV viremia
were achieved. However, treatment failure
rates, typically a consequence of suboptimal
adherence to regimens requiring three times a
day administration and/or large numbers of pills,
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were common. In a study from the Johns
Hopkins HIV clinic in Baltimore, only 37% of
their patients starting their first protease inhibitor
(PI) based regimen between 1996 and 1998
had HIV viral load levels below the limit of
detection (500 copies/mL).2 An analysis of drug
resistance from this early era of potent HIV therapy found that two thirds of individuals in a representative sample of patients receiving HIV
therapy in the US had HIV viremia of at least
500 copies/mL; of these 76% had evidence of
drug resistant virus on testing.3
Of course, many of the patients developing
resistant HIV had previously been exposed to
suboptimal regimens, leading to the cultivation
of drug resistance mutations of the virus that
hamstrung their subsequent combination therapies. A recent study of drug resistance conducted at the HIV clinic at The University of North
Carolina, found that starting therapy with a regimen that did not contain a PI or a non-nucleoside reverse transcriptase inhibitor (NNRTI) as
part of a three-drug combination was a strong
predictor of triple class (i.e. NRTI, NNRTI and
PI) drug resistance.4 Interestingly, of those few
patients who started on a triple drug regimen
containing a PI or NNRTI but developed triple
class resistance, almost all were on a PI that
was not co-administered with ritonavir (i.e. unboosted PIs).
Heavy reliance on highly potent ritonavir-boosted PIs and NNRTIs as the anchors of HIV therapy has led to a profound suppression of HIV
replication, hampering the development of drug
resistance. Studies of ritonavir-boosted PI regimens have consistently demonstrated that virologic failure to these agents is rarely associated
with resistance to the PI, but rather to the comContinued on page 3
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Dear Corrections Colleagues,
As we reflect on the year that is slipping away, one thing is clear - it was not boring. For those of
us involved with the management of infections in our prisons and jails 2006 brought much for us
to consider (and lots for us at IDCR to cover) including the Institute of Medicine report on research
in prisons, the investigation of the transmission of HIV infection within the Georgia Department of
Corrections reported in the MMWR, new CDC recommendations on screening for HIV infection,
updated guidelines on initial antiretroviral therapy, the approval of a new HIV protease inhibitor
and a vaccine for human papilloma virus and the brisk spread of community acquired MRSA. All
of this in addition to our usual coverage of conferences, our interviews with experts and IDCR's
symposium at the NCCHC conference.
The past 12 months have also seen some changes here at IDCR. The newsletter is now independent of Brown University. Further, we have developed close ties with the American Academy
of HIV Medicine (AAHIVM), and we have expanded to include additional content with each issue.
Reflecting on our achievements this year, I can only be proud of our staff, board and authors. Our
Managing Editor, Elizabeth Closson, in particular, has been essential to getting the newsletter to
you every month.
Since becoming Chief Editor, my goal has been to produce a newsletter readers would want to
read and keep handy for future reference. The IDCR coverage of the management of depression
in the setting of HIV, tuberculosis, hepatitis B virus and infection control are examples of issues
that clinicians within and outside of corrections continue to find useful.
In this month's issue, we continue to strive to keep you informed. Our interview with the CDC's Dr.
Richard Wolitski provides an indepth look at an important HIV/STD prevention trial conducted in
four state prisons and highlights the challenges we continue to face in trying to reduce risky
behaviors. As we increasingly rely on HIV resistance testing, we have included answers to some
of the most commonly asked questions regarding drug resistance and try to un-code the mystery
surrounding resistance.
At the cusp of 2007, we are working to create a line-up of issues that will continue to be useful
and informative. One thing I can promise, it won't be boring.
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(continued from page 1)
panion drugs in the regimen.5-7 In contrast,
virologic failure to NNRTI-based regimens
is more likely to be accompanied by
detectable resistance to the NNRTI, often in
tandem with the M184V (see HIV 101)
mutation that confers severely reduced susceptibility to lamivudine (3TC) and emtricitabine (FTC)8-9 (See Resources for link to a
guide to reading HIV genotype resistance test).

Recently presented results from an AIDS
Clinical Trials Group (ACTG) study in which
treatment-naïve patients were assigned to 2
NRTIs plus the NNRTI efavirenz (EFV) versus 2 NRTIs plus the boosted PI
lopinavir/ritonavir (LPV/r) provides some
insights into the frequency of drug resistance with current ART.8 After 96 weeks,
both of these study groups experienced
high levels of virologic suppression below
50 copies/mL (89% for EFV versus 77% for
LPV/r; p = 0.003). Study defined virologic
failure (a lack of 10 fold or greater drop in
viral load, virologic rebound before week
32, failure to suppress to less than 200
copies/mL after 32 weeks or rebound after
week 32) was observed in 94 of the 253
subjects randomized to LPV/r + 2 NRTIs
and 60 of the 250 assigned to EFV + 2
NRTIs. For the LPV/r + 2 NRTI arm, 52 of
these 94 had resistance testing results
available and 8 had NRTI mutations detected but none had any major PI mutations
evident. In contrast, 33 of the 60 subjects
on EFV + 2 NRTIs with genotype results
available had one or more NRTI mutations
detected and 16 (48% of those with genotypes in this arm) had NNRTI resistance.
The take-home lesson from this trial and
other studies of resistance to current ART
regimens is that the great majority of
patients treated with ART will achieve virologic suppression. Of those who do experience virologic failure, a substantial proportion does not have drug resistance evident
at the time of failure. For some of these
patients, a total lack of adherence could
explain this observation as the absence of
drug removes the selective pressure
applied by ART and permits non-resistant
wild-type virus to rebound. In other cases,
the presence of drug resistance appears to
be influenced by the composition of the regimen, with resistance rarely detected when
regimens contain a ritonavir-boosted PI.
How adherent must patients be to avoid
drug resistance?
The dogma for several years has been that
HIV-infected individuals receiving ART
should take, at a minimum, 95% of the
doses of medication prescribed. This
canon of HIV management was rooted in
the findings of an important study conducted in the late 1990s in a Veteran's
Administration hospital in Nebraska in
which adherence to HIV therapies was
monitored using electronic medication bottle caps that recorded the opening of the
medication bottle.10 In this study, adher-
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ence at 95% or better was associated with
the least risk of uncontrolled viremia with
only 22% of patients at this level of adherence having a viral load >400 copies/mL
compared to 61% with adherence between
80% and 95%. Lower levels of adherence
were associated with even greater rates of
detectable virus. It should be noted that
patients in this study had varying degrees of
treatment experience; for some this was the
first regimen and others were highly treatment experienced. Further, in this cohort,
PIs were commonly used and were not
boosted with ritonavir.
The advent of boosted-PIs and the emergence of NNRTIs since this study was conducted have likely shifted the required
adherence level downward as these medications achieve high concentrations in the
blood plasma, have relatively long half
lives, and, in the case of boosted-PIs, are
relatively 'resistant' to resistance. While it
remains unclear just how adherent patients
need to be to the potent therapies now
available, there is some evidence that rates
of virologic failure to these therapies can be
low even when adherence falls below 9095%. Provocative work by David
Bangsberg and colleagues at UCSF suggests that adherence to our current first line
therapies may not need to be absolutely in
the range of 90%-100% for these regimens
to achieve and maintain viral suppression.
In his studies of a cohort of marginally
housed HIV-infected men and women in
San Francisco, he found that the risk of
resistance to NNRTI-based regimens
increased only when adherence dropped to
below 54%.11 Above this level of adherence, the overwhelming majority of patients
had viral loads of < 400 copies/mL. With
unboosted-PI-based therapy, a more linear
relationship between adherence and suppression of viral replication, as described by
the VA group in Nebraska, was observed,
with viral suppression inversely proportional
to adherence level. Modeling data suggest
that adherence to regimens with the potency of ritonavir-boosted PIs should produce
similar resistance rates as seen for
NNRTIs.12
This does not mean that patients should not
be encouraged to take all their medications
as directed. Patients should continue to be
encouraged to take their medications exactly as directed. The San Francisco study
results have yet to be replicated by others.
Further, the study used 400 copies/mL as a
threshold for undetectable rather than 50
copies/mL and low level virus may increase
risk of resistance development over time.
Individual variability in drug metabolism and
other factors may make it dangerous to
apply the aggregate data from this particular investigation to a patient. However, at
the same time clinicians should appreciate
that the 90%-95% adherence threshold we
have held our patients to may no longer be
justified when NNRTI- or ritonavir-boosted
PI-based therapies are used in patients with
susceptible virus. This is important when
considering the administration of punitive
responses to ART adherence levels that are

3
below 90%. In some prisons and jails,
adherence below a certain level may lead to
treatment discontinuation. While the rationale for such an approach is sound, the
adherence threshold chosen may need to
be less rigid and reflect the available data
on current potent ART regimens. These
data suggest a more accurate level may be
lower than 95% for NNRTIs and probably
for boosted PI-containing regimens.
The genotype says there is no resistance. Can I be sure of that?
HIV drug resistance tests have been incredibly useful to clinicians managing HIV infection. However, as with any tool or test, it is
important for the user to understand their
limitations (See Resources for link to a comparison of HIV resistance test).
HIV resistance tests can detect a drug
resistant virus that is present in sufficient
numbers. If a resistant viral strain exists in
very low numbers, the tests will likely miss
it. Therefore, resistance can be present at
low levels and not be picked up by the
resistance tests. This is more likely to happen in several situations. For example,
sometimes a resistance test is performed
when there is very little virus around (i.e. a
viral load of 1,000 copies/mL or less). As
the overall amount of virus is low, the HIV
drawn into the sample for testing may not
be very representative of the viral population present in the circulation and resistant
mutants may have been missed. Similarly,
when a patient has developed drug resistance and then stops their medication, the
wild-type (not drug resistant) virus reemerges as it can now replicate freely with
the removal of the HIV drugs. As the wildtype grows, it dilutes the population of the
resistant virus, making it harder to detect.
Importantly, even though the wild-type
increases to great numbers, the resistant
virus is not gone but continues to be present in low numbers and, under the right
conditions, such as re-application of the
HIV medications, can be selected to grow
preferentially. It is currently believed that
once a resistant virus is cultivated, it never
disappears, but poses a lingering threat to
the responses to future ART.
How often do people get infected with
drug resistant virus?
The answer to this question depends on
where the person with HIV is infected. In
major cities of the US and Europe, anywhere between 10-25% of people acquiring
HIV are infected with HIV that is resistant to
at least one HIV drug.13-18 In all studies,
resistance is highest among the ART drug
classes to NRTIs and increasingly to
NNRTIs, followed by PIs. Data from New
York, which may well represent a worstcase scenario, found an increase over time
in acquired ART resistance among 361 individuals with acute or recent HIV infection
diagnosed
between
1995-2003.14
Comparing the periods of 1995-1998 and
Continued on page 4

December 2006

HIV

Vol. 9, Issue 11

DRUG RESISTANCE...

(continued from page 3)
2003-2004, rates of ART resistance
increased from 13% to over 24%. NRTI
resistance was the most prevalent but was
relatively stable. PI resistance was fairly
uncommon (1.3%) in the earlier period but
rose to 7.1% of patients in the more recent
period - a trend that did not reach statistical
significance. For NNRTIs, resistance paralleled their popularity with a significant rise
from 2.6% to more than 13%. Other studies
of recently infected patients in other locations generally report a slightly lower prevalence of drug resistance than found in this
study.
Studies of drug resistance in chronically
infected but treatment-naïve patients have
also been reported.13,17 In one study of 491
patients under care in 25 US cities from
1999-2001, 11% had at least one ART
resistance mutation detected.13 Most of the
mutations detected were those that reduce
susceptibility to the NRTIs, especially the
thymidine analoges and 3TC/FTC.
The rate of transmitted drug-resistance in
non-metropolitan areas such as rural
regions of the US South - where most people with HIV infection in this country live - is
not clear. What has become evident is that
acquired drug resistance has ramifications
for subsequent treatment success.
Several studies have observed increased
rates of treatment failure in patients with
pre-therapy resistance.19-22 Although wildtype virus may be able to out-compete
resistant mutants, some resistance mutations can persist at levels that permit longterm detection by resistance assays; mutations conferring resistance to all three of the
initial ART classes have been described in
chronically infected, treatment-naïve
patients. For these reasons, the US
Department of Health and Human Services
(DHHS) guidelines on initial therapy of HIV
infection, updated in October 2006, recommend genotype resistance testing be performed in all treatment naïve patients prior
to initiation of HIV therapy.23

What does it mean when someone says
that resistant virus is "less fit"?
In vitro studies and some clinical trials suggest that certain mutations of HIV in
response to drug therapy may reduce the
pathogenicity of the virus.24-26 To understand how resistance can impact the ability
of the virus to replicate it is helpful to consider the dynamics of HIV replication in
terms of basic Darwinian evolution. Within
the body of an HIV-infected individual ART
selects for mutated virus that can survive in
a milieu includes these drugs. Continued
pressure by the ART favors the persistence
of such drug resistant virus. However, in
many types of drug resistant mutations the
virus evolves to evade the effects of drug
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therapy but comes with a cost to their ability to replicate relative to wild-type virus.
That is, drug resistant virus, in becoming
mutated, may not work as well as virus that
does not contain drug resistance mutations.
In some cases, the reduced fitness of resistant virus can be exploited during therapy to
slow the pace of disease progression.
Specifically, in cases where there are few
antiretrovirals to which the virus remains
susceptible the continued use of certain
agents to which the patient's virus is known
to be resistant may be used to maintain levels of the relatively less 'fit' resistant virus.
The best example of this effect is found in
the M184V resistance mutation. This mutation essentially neutralizes any antiviral
activity of 3TC and FTC. However, this
mutation has been reported to inhibit the
ability of the virus to replicate and may sensitize resistance virus to the effects of AZT
and tenofovir. In one study, patients failing
3TC-containing therapy with a M184V
mutation were randomized to continue their
3TC alone as mono-therapy or stop all ART.
27 Those that continued on 3TC alone had
a truncated rise in HIV viral load and
reduced declines in CD4 cell counts compared to those who were no longer taking
ART. Thus, continued 3TC had some effect
on viral replication even though the M184V
mutation was evident. Some clinicians take
advantage of this phenomenon and maintain 3TC or FTC as part of salvage regimens in patients with drug resistance that
includes the M184V mutant.
Whether resistance to other antiretrovirals
can yield similar effects on fitness is being
studied. There is some evidence that resistance to the thymidine analogues (AZT and
stavudine), as well as the K65R mutation
that can be selected for during therapy with
tenofovir as well as some NRTIs, have a
detrimental effect on viral fitness. What is
clear though, is that it is probably not wise
to maintain an NNRTI when resistance to
this class of drugs is detected. Unlike the
major NRTI mutations and the constellation
of mutations that are usually needed to
reduce susceptibility to the PIs, the primary
NNRTI mutations seem to have less of an
effect on the replication ability of HIV. This
may explain why the K103N NNRTI mutation can remain detectable by genotype
resistance testing long after NNRTI exposure. Further, early clinical trial data of a
second generation NNRTI, etravirine (TMC125), indicate reduced response to this new
agent with an accumulation of NNRTI resistance mutations.28 The bottom line is that,
in general, maintaining NNRTI therapy in
the face of documented NNRTI resistance
mutations should not be done. This is not to
say that continued therapy with a PI or
NRTI could not also lead to the accumulation of additional mutations once resistance
has developed. It can, and continuation of
any ART to which the virus is resistant has
to be considered very carefully when effective treatment remains available.

4
What is the best way to manage patients
who have developed resistance to many
drugs and ART classes?
The best way to manage resistance is introduction of drugs to which additional resistance has not developed. A number of new
drugs in new classes are being developed
and are expected to become available to
patients within the next two to five years.
These include inhibitors of the HIV integrase enzyme and the processes that lead
to viral maturation within a CD4 cell, blockers of the CCR5 co-receptor and the CD4
receptor, as well as new drugs in existing
classes. In addition, there are recently
approved antiretrovirals that have activity
against certain types of resistant virus that
can be employed to craft a new regimen
when a prior combination fails.
Whether using new novel agents, existing
drugs, or recycling previously used regimens to which the virus is not considered to
have resistance, the principle remains the
same: use as many drugs in the new regimen as possible that have activity against
the virus that exists in that patient. Studies
of new antiretrovirals in treatment-experienced patients have consistently demonstrated that when these drugs are coupled
with agents to which the virus remains susceptible, response to therapy is better.29-31
We are approaching a critical mass of
potent therapies that can be used in such
salvage regimens. With the approvals of the
tipranavir and darunavir - PIs that are
boosted with ritonavir and have activity
against many strains of virus resistant to
other PIs - plus the availability of enfuvitide
(T-20), new regimens that offer a reasonable chance of success can be devised.
Studies of both of these PIs demonstrate
unprecedented responses in treatmentexperienced patients, especially when used
with other active drugs.29-31
Etravirine, the next generation NNRTI; MK0518, the first HIV integrase inhibitor and
maraviroc, a CCR5 inhibitor are all offered
via expanded access programs. While
these therapies will remain out of reach for
most correctional facilities until FDA
approval, they offer the promise of effective
agents that, when available, can complete
an attractive salvage regimen. For this reason, patients with multiple drug resistant
virus may be best managed, when possible,
by a delay in a change of therapy until one
or more of these new agents becomes
available.
Other than counseling my patient
regarding adherence what else can I do
to reduce the risk of HIV drug resistance?
While it is ultimately the patient's responsibility to take his or her medication, the clinician must chose regimens that are sound
and are most likely to provide long-term
Continued on page 5
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viral suppression. Initial therapy should be
prescribed with the goal of long-term viral
suppression. There are antiretroviral regimens that have been found to be less effective than the currently recommended firstline therapies. Some, like the fixed dose
combination of abacavir, 3TC and AZT
have been found to be suboptimal compared to preferred regimens. Other combinations have been found to be outright dangerous (e.g. all other triple NRTI regimens
except, perhaps, tenofovir + 3TC or FTC +
AZT) and should never be prescribed. The
US DHHS recommendation for ART for
adults and adolescents is a user-friendly
guide to initial therapy and lists clearly the
preferred regimens, alternatives for special
cases and completely contraindicated combinations.23 Unless there is an extremely
compelling rationale, the drugs listed in the
preferred regimens should be used in all
cases of initial HIV therapy.
Baseline genotypic resistance testing prior
to the start of HIV therapy is becoming less
and less optional. The guidelines are clear
on the utility of this test in reducing downstream problems for patients and a recent
analysis suggests such testing is costeffective.23 Detecting transmitted resistance or mutations that may linger from
prior ART exposure can help guide proper
treatment during the incarceration and after
release. The price of the genotype resistance assays has come down, making cost
less of a justification for ignoring the DHHS
recommendations.
HIV clinicians have become accustomed to
evaluating HIV-infected patients every three
to four months. However, clinicians must be
attuned to the development of changes in
the viral load that may signal the emergence of drug resistance and act on these
data prior to the next patient visit.
Unexpected changes in viral load should
prompt immediate reevaluation of the

patient and the drawing of a genotype resistance test. At the North Carolina
Department of Corrections, we are able to
order a genotype and if the viral load is
undetectable, the genotype is not run by the
commercial laboratory - thus, avoiding
unnecessary billing. Prompt action can prevent further cultivation of resistance that
can handicap future treatment options.
For patients new to the system, the greatest
challenge can be determining what therapies they have been exposed to in the past.
As tiresome as it is, obtaining a release of
information and old records from outside
providers can ultimately be time- and
money-saving. In cases where little can be
learned about the prior ART history, restart
of the last regimen (if it is not some bizarre
combination) can be attempted with a
genotype obtained after two to four weeks
to detect major resistance mutations that
may lead to the overhaul of this regimen.
So as not to perpetuate the 'black box' of
HIV treatment history, inmates should be
given a record of their medications prior to
release. Wallet-sized cards that can list HIV
medications and other essential clinical
data are available from at least two pharmaceutical companies. 'Home-made' version created by corrections staff can work
equally as well. When possible, a listing of
the major ART resistance mutations should
be added to these cards for the benefit of
the patient's future providers.
Lastly, salvage regimens should be created
with considerable thought. Salvage HIV
therapy generally yields diminishing returns
with each subsequent combination less
likely to be effective compared to the previous. New therapies may help increase the
odds of treatment success beyond initial
therapy but, it continues to be imperative
that active agents not be wasted by being
included in regimens that are predicted to
be impotent based on resistance or patient
history (i.e. if the patient was on AZT mono-

therapy for six years in the 1980s, it is safe
to assume they are resistant to this medication even if the resistance test does not
detect AZT associated mutations). There
should be a low threshold for consultation
with an HIV expert when considering the
management of the treatment-experienced
patient. Outreach to such experts in the
community, at academic medical centers or
other correctional facilities should be
sought and lines of communication established.
Summary
Resistance happens. However, resistance
to HIV medications need not be inevitable.
Potent therapies are now available in
extremely convenient formulations and
dosing schedules. Adherence remains a
cornerstone of drug resistance prevention
and correctional facilities have unique
advantages in the monitoring and encouragement of treatment adherence. In addition, close surveillance of response to HIV
therapy and quick action when viral load
increases are detected can forestall further
damage from evolving mutations. New
drugs in existing classes that are already
FDA approved and those expected to be
shortly, hold the promise of a new chance
for many patients who have developed HIV
drug resistance. Wise use of these medications based on clinical trials data, patient
history and detected and suspected ART
resistance will increase the odds for treatment success.

Go to www.AAHIVM.org to learn about membership, continuing education and the new
partnership with IDCR
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IDCR-O-GRAM
2006 DHHS Guidelines for the Utilization of Drug Resistance Testing in Clinical Practice
HIV drug resistance testing is recommended for persons with acute HIV infection if the decision is made to initiate therapy at this time
(BIII). If therapy is deferred, resistance testing at this time should still be considered (CIII).
Drug resistance testing is also recommended for persons with chronic HIV infection prior to initiation of therapy (BIII). Earlier testing
may be considered (CIII).
A genotypic assay is generally preferred for antiretroviral-naïve persons (BIII).
HIV drug resistance testing should be preformed to assist in selecting active drugs when changing antiretroviral regimens in cases of
virologic failure (BII).
HIV drug resistance testing should also be considered when managing suboptimal viral load reduction (BIII).
Drug resistance testing in the setting of virologic failure should be preformed while the patient is taking his/her antiretroviral drugs, or
immediately (i.e., within 4 weeks) after discontinuing therapy (BII).
Drug resistance testing is not advised for persons with viral load <1,000 copies/mL, because amplification of the virus is unreliable
(DIII).

Rating Scheme for Recommendations
Strength of Recommendation: A= Strong B= Moderate C= Optional D= Should usually not be offered E= Should never be offered
Quality of Evidence for Recommendation: I= At least one randomized trial with clinical results II: Clinical trials with laboratory results III: Expert opinion
Source: The US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.October 2006. Available
at http://aidsinfo.nih.gov/.
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SPOTLIGHT - INTERVENTIONS TO REDUCE HIV AND STD TRANSMISSION RISK BEHAVIORS
FOLLOWING PRISON RELEASE - A CONVERSATION WITH DR. RICHARD WOLITSKI
The results of the START Study, a randomized controlled trial of interventions to
reduce HIV/STD risk behaviors among 522
young men being released from prison in
four states (California, Mississippi, Rhode
Island and Wisconsin), were recently published in the American Journal of Public
Health. IDCR Chief Editor, Dr. David Wohl,
spoke with Dr. Richard Wolitski, lead author
of the study, which was supported by the
Centers for Disease Control and Prevention
(CDC). Dr. Wolitski is the Acting Deputy
Director for Behavioral and Social Sciences
in the CDC's Division of HIV/AIDS
Prevention.
David Wohl (DW): You led what many consider to be a very important and unique
study looking at reducing HIV and STD risk
behaviors among young men released from
prison. Could describe the two interventions
that were studied?
Richard Wolitski (RW): The Project START
intervention was collaboratively developed
by researchers at the four sites and CDC. It
compared the relative efficacy of two different interventions. The first intervention was
a single-session intervention that was conducted before participants were released
from prison. The single-session intervention
was based on a brief HIV risk assessment
and risk-reduction planning intervention
developed by Grinstead and colleagues that
had previously been shown to reduce risk in
this population. We compared the effects of
the single-session intervention with those of
the six-session enhanced intervention.
The enhanced intervention was meant to
provide a bridge between incarceration and
then reintegration into the community. The
enhanced intervention had two sessions
that were conducted before participants
were released. The first of these was identical to the single-session intervention, and
the second session focused more broadly
on the individual participant's needs after
release. It included an assessment of needs
and planning for housing, employment,
financial problems, social relationships, and
avoiding reincarceration. Then participants
had four additional scheduled interventions
after release. These interventions were
client-centered and adopted elements of
prevention case management and motivational interviewing.

also made it possible for the participants to
receive additional sessions as needed during the three-month intervention period following release. There weren't that many
people who received additional sessions.
There were a total of just 91 additional
enhanced intervention sessions that were
delivered to 49 participants, and most of
those, 61%, received only one additional
session.

practice safer sex with their main partners,
more so than non-main partners, and studies of HIV-infected releasees have shown
that HIV-infected former inmates are more
likely to practice unsafe sex with their main
partner, with whom they may feel more comfortable with than casual partners. The finding that the intervention seemed to work
more so with the main partners seems particularly significant.

DW: What were the main results of the
study?

RW: One of the things to understand about
this population is that many of the men had
already reduced their risk with their nonmain partners and that the highest levels of
risk were observed with main partners. So, I
think in part what's happening here is that
the enhanced intervention sensitized men to
the potential risks of contracting HIV or
another sexually transmitted infection from
their main partners or also sensitized them
to the possibility that they might be putting
their main partner at risk. Many of these
main partners were also at risk --- one third
of the men who had a main partner believed
that this partner had one or more risk factors
for HIV, hepatitis or other sexually transmitted infection.

RW: The enhanced intervention was associated with a significant overall reduction in
sexual risk behaviors 24 weeks after
release. More specifically, we found that
men who received the enhanced intervention were significantly less likely to report
unprotected sex the last time they had sex
and during the full recall period. Although
there was a significant overall reduction in
sexual risk, this reduction was due almost
entirely to reductions in risk with the participants' main or primary partners.

“These interventions were guided by
a harm-reduction philosophy that
focused on goals that were developed by the participants and it was
grounded in a holistic approach that
addressed the men's reintegration
needs, such as competing needs
related to employment, housing,
substance abuse and legal issues.”
DW: There are few studies that have shown
positive changes in risk behavior in general,
and certainly there remains very limited data
about interventions for an incarcerated or
recently incarcerated population. However, I
was surprised that we did not see greater
differences at week 12 - at the end of the
enhanced intervention. The only significant
difference was seen at week 24, which is
three months after the intervention was
completed. Any thoughts about why you saw
a greater effect after the intervention ceases?

DW: When I think about that kind of case
management and a client-driven approach, I
would think that there might be some variability in the frequency with which case
managers, following release, would interact
with participants. Was there any freedom on
the part of the case managers in the
enhanced intervention or were they restricted to only four sessions with the participant
after release?

RW: That's a really good question. One
thing that's important to keep in mind is that
at the 12-week interview, the participants
were asked about their risk behavior since
their first week of release from prison. The
period of time that participants are reporting
on includes a time period where enhanced
intervention participants had received very
little of the intervention, so it's really only at
the 24-week assessment that we can look at
behavior change after participants had a
chance to receive the full intervention.

RW: All the participants were scheduled to
receive four scheduled interventions, but we

DW: You mentioned that the enhanced intervention seemed to motivate participants to

DW: Are there any plans to evaluate longerterm differences between the study arms,
beyond week 24?
RW: At this time, we don't have any plans to
do that. However, the CDC is supporting the
packaging of the Project START intervention
for dissemination to the CDC's prevention
partners. This means that there will be additional opportunities to evaluate the effectiveness of this intervention as it is being delivered by local agencies.
DW: Do you think, given what you now know
from looking closely at the results, that a
three-month post-release intervention is sufficient?
RW: A three-month post-intervention followup is an acceptable standard in the field,
and this follow-up is longer than others that
have been used in HIV prevention studies
with incarcerated men. Certainly, having a
longer follow-up is better, but it requires
additional resources that were not available
for this study. It's possible that, given the
comprehensive nature of this intervention,
some of the participants established a stable
pattern of behaviors that allowed them to
maintain reduced risk behaviors over time.
But we really don't know that at this point in
time.
DW: The results that you found at week 24
after release were significant, but 68% of
those receiving the enhanced intervention
reported unsafe risk behaviors, albeit versus
78% of those in the single session arm.
How could anyone get excited about over
Continued on page 8
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two thirds of the people in the enhanced
intervention still practicing risky behavior?
RW: We have to be realistic about what any
one intervention can accomplish. A lot of
people would have thought that it would be
difficult or impossible to see any risk reduction in this population. As you know, incarcerated men are sometimes viewed as people who really don't care about their own
health or the health of their partners, and
this study demonstrates that it is actually
possible to motivate these men to reduce
their risk behavior. It does indicate, though,
that there is a need for additional intervention for some men, or perhaps different
types of intervention for men who did not
respond to this particular intervention.
DW: Your study concentrated on people following release, and a common misperception, is that HIV-infected people in prison
acquire their infection during incarceration.
The CDC took a lead with a study of an outbreak of acute or transmitted HIV within a
correctional system in Georgia. Your study
focused on people getting out of prison, versus an intervention to try to reduce acquisition of HIV within a correctional system.
Why?
RW: One thing that is important to keep in
mind is that incarcerated men continue to be
part of the communities that they came
from, and that most men who are incarcerated will be re-released back into the community. Addressing this period of transition
from incarceration to release is really critical
for public health. We chose to focus on this
period after release in part because we

wanted to design an intervention that would
be feasible for health departments or community-based organizations to implement in
collaboration with local correctional facilities.
So our primary interest here was driven by
the types of organizations that we thought
might be implementing this intervention in
the future.
DW: Right. In your conclusion to the paper
you call upon community-based organizations and health departments to work in tandem with correctional institutions to improve
the well-being of people such as those who
enrolled in your study. Given what you've
learned and your experience, what do you
see as being obstacles to that kind of cooperation and how your results might help us
to overcome them?
RW: The most important thing that this study
shows is that this type of intervention is feasible and can be efficacious in reducing risk
behavior among incarcerated young men.
There are a number of challenges that people face when coming from outside correctional settings and trying to conduct this type
of intervention, and one of the biggest challenges is gaining entry into the facilities.
What we hope is that this paper and this
study will give health departments and community-based organizations that are interested in establishing those relationships
with correctional facilities a model that they
can show to local correctional facilities to
show that this can work.
DW: You mentioned earlier that the intervention is going to be packaged and
become more accessible. Any details about
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how those who are interested in learning
more about the program can get the materials to actually start to implement their version?
RW: Probably the best thing that I could do
is to refer people to the CDC website
(www.cdc.gov/hiv/PROJECTS/ProjectSTAR
T), where there is additional information that
is online about the study. The actual intervention package will not be available for
another year or two, from the CDC. Some of
the local researchers may be willing to provide additional information in the interim, but
readers would have to contact them directly.
The contact information for all principal
investigators is listed on the Project START
website.
DW: So, summing-up, the take-home
lessons from the START Study seem to be
that, even in this difficult-to-reach and difficult-to-change population, you can see
some change in risky behavior in a positive
direction, and while this is encouraging, the
results certainly points to the need for further
development of interventions to complement
this one. Is that fair to say? Is there anything
more you'd say to expand upon that?
RW: I think that's a good summarization of
the study, and I would say that Project
START can be an important part of a comprehensive strategy for reducing HIV transmission among incarcerated men and their
sex partners. Other elements of that
approach include HIV testing upon entry
and release from prison, as well as interventions that are designed specifically for
persons living with HIV and AIDS.

HIV 101
The Anatomy of an Antiretroviral Resistance Mutation

M 184 V
First letter denotes the amino
acid that should be at this
codon position of the HIV
genome. In this case the 'M'
stands for methionine.

The number designates the
position in the HIV genome
where the switch in amino
acids is taking place. Here it
is at the 184 position, which
is located in the region where
the virus's genes for the
reverse transcriptase enzyme
are located.
Resistance to a reverse transcriptase inhibitor would be
expected to be located in this
region.

The letter at the end indicates
what amino acid replaced the
one that should have been
located at this codon. Here a
valine was substituted for the
methionine, leading to a
structural change in the
enzyme that renders the virus
resistant to 3TC and FTC.
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NEWS AND LITERATURE REVIEWS
Sexual Violence Inside Prisons

14th Annual Ryan White National
Youth Conference on HIV and AIDS
Oakland, CA
February 17-19, 2007
Visit:www.napwa.org/rwnyc/index.html

Given the many associated public health consequences of sexual violence, Wolfe et al. conducted a
study to estimate the prevalence of sexual victimization within an unidentified state prison system. The
weighted estimates, which were constructed by gender and facility size, show that rates of inmate-oninmate sexual victimization, defined as either abusive
sexual contact (intentional touching of specified
areas of the body) or nonconsensual sex acts (forced
sex acts, including oral and anal sex), in the previous
six months were highest for female inmates (212 per
1,000), more than four times higher than the rates for
males (43 per 1,000). Additionally, abusive sexual
conduct, was more likely between inmates and
between staff and inmates than nonconsensual sexual acts, such as rape. These results were based on
an audio-computer assisted interviews administered
to 6,964 male and 564 female inmates housed in the
twelve prison facilities. Extrapolating from the estimates, the authors suggest that the number of potential victims susceptible to HIV and other health consequences of sexual victimization could be as high as
22,000 male and over 3,200 female inmates on a
national level. These staggering numbers underscore the need for targeted interventions to reduce
this level of abuse.

14th Conference on Retroviruses and
Opportunistic Infections
Los Angeles, CA
February 25-28, 2007
Visit:www.retroconference.org/2007/

Sexual Violence Inside Prisons: Rates and
Victimization. Wolff, N et al. Journal of Urban Health.
2006;83(5):835-48.

American Correctional Association
Winter Conference
Tampa, FL
January 19-24, 2007
Visit:www.aca.org/conferences/winter07/
2007 National African American MSM
Leadership Conference on HIV/AIDS:
"Brothers, It's Our Time"
Charlotte, NC
January 25-28, 2007
Visit:www.aesmonline.com
/Conference.htm
The 2nd National Conference on
Methamphetamine, HIV, and Hepatitis
Salt Lake City, UT
February 1-3, 2007
Visit:www.xmission.com/~uhrcmeth/registration.php
2007 National Conference on AfricanAmericans and AIDS
Featuring the Rev. Jesse L. Jackson
Philadelphia, PA
February 12-13, 2007
Visit:www.minority-healthcare.com

Interferon and Ribavirin in Hepatitis C
Virus Infection:
Mechanisms of Response and NonResponse
Chicago, IL
March 1-3, 2007
Visit:www.aasld.org/eweb/DynamicPage.
aspx?webcode=07_hepatitisstc
Academic and Health Policy
Conference on Correctional Health
Sponsored by the University of
Massachusetts Medical School
and UMass Correctional Health
Boston, MA
March 29-30, 2007
Visit:www.umassmed.edu/commedinterior.aspx?id=33110
16th Annual HIV Conference of the
Florida/Caribbean AIDS Education and
Training Center
Orlando, FL
March 30-31, 2007
Visit:www.faetc.org/Conference/
Updates in Correctional Health Care
Orlando, FL
May 5-8, 2007
Visit:www.ncchc.org/education
/index.html
IAS 2007: 4th IAS Conference on HIV
Pathogenesis, Treatment and
Prevention
Sydney, Australia
July 22-27, 2007
Visit:www.ias2007.org/start.aspx
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Incarceration as Forced Migration: Effects on
Selected Community Health Outcomes
Researchers at the University of North Carolina, utilizing data from each of the 100 counties in that state,
found that county rates of sexually transmitted infections (STI) and teenage pregnancies consistently
increased with increasing incarceration rates.
Thomas and Torrone obtained the results, which are
published in the American Journal of Public Health,
by calculating the correlation between rates of incarceration in state prisons and county jails and rates of
STIs and teenage pregnancies during the period of
1995 to 2002. The authors use the strong associations, especially between teenage pregnancy and the
most common STIs, to propose that high incarceration rates have the unintended consequence of
destabilizing communities and contributing to
adverse health outcomes. Specifically, they note that
fewer than one half of one percent of reported gonorrhea and chlamydial infections in 2000 were reported
in correctional facilities, suggesting that many of the
adverse effects are felt most strongly in the community, rather than the prison. The high rates of incarceration, the authors state, create a situation of
"forced migration", not unlike that found in South
Africa in the late 1930's, greatly altering gender
ratios, which have been shown to affect rates of
teenage pregnancy, and STIs such as syphilis, and
gonorrhea. Despite the correlation, the authors do
not believe that the negative community health
affects alone will create a dramatic policy shift regarding alternatives to incarceration.
Incarceration as Forced Migration: Effects on
Selected Community Health Outcomes. Thomas, JC
et al. American Journal of Public Health.
2006;96(10):1762-65.

Chlamydia trachmomatis and Neisseria gonorrhoeae Infections Among Men and Women
Entering California Prisons
Due to the limited amount of information regarding
the prevalence of bacterial STI infection in prison
based settings, Bernstein et al set out to estimate the
prevalence of Chalmydia trachomatis and Neisseria
gonorrheae among newly arrived inmates at six
California prisons. The cross sectional study of 698
men aged 18 to 25 years and 572 women aged 18
years and older revealed a high prevalence of C trachomatis in both groups. Among men aged 18 to 25,
the overall prevalence was 9.9%, while women of the
same age exhibited a prevalence of 8.9%. The
prevalence among all women was 3.3%. In contrast,
only three cases of N. gonorrhoeae were detected
with an overall prevalence of 0.24%, which was consistent with recent findings from other settings. The
study of men was limited to an examination of those
between the ages of 18-25, and given the high prevalence among this group, further study of all men
entering prison may be justified. Despite the limitations, the authors suggest that the high prevalence of
C. trachmatis infection, especially among young
female and male inmates, supports routine screening
upon entry into prison. Furthermore, the authors
assert that screening in a jail setting, prior to entry
into prison, may represent an excellent opportunity to
identify and treat these infections, thus preventing
complications and the burden of infection among this
high-risk population.
Chlamydia trachmomatis and Neisseria gonorrhoeae
Infections Among Men and Women Entering
California Prisons. Bernstein, KT et al. American
Journal of Public Health. 2006;96(10):1862-66.
Implementing a Routine, Voluntary HIV Testing
Program in a Massachusetts County Prison
Working within a Massachusetts county jail,
researchers found that the implementation of a routine, voluntary HIV testing program resulted in a significant increase in testing rates among inmates. The
study, published in the Journal of Urban Health,
details the program in which inmates were provided
group counseling and then offered private HIV testing. Among the group receiving intervention, 73.1%
(734 of 1,004) of eligible inmates accepted testing,
compared to 18.0% (318 of 1,723) of inmates in the
control group, receiving only inmate or physician
requested testing. The most commonly cited reason
for refusal in the study group was "tested in the prior
year" (47.5%), followed by "not at risk" (29.4%).
These results indicate a higher level of acceptance
than previous studies of correctional HIV testing, due
perhaps, the authors suggest, to improvements in
HIV treatment or testing a population with a high
background testing rate. Of the study group, 457 or
45.5% had been tested for HIV in prior years, most
receiving their last test within a prison setting
(78.2%). While cautioning against over-testing and
redundancy among inmates, the authors use their
results to emphasize that routine HIV counseling,
testing, and referral is acceptable to inmates and
results in high rates of testing.
Implementing a Routine, Voluntary HIV Testing
Program in a Massachusetts County Prison.
Liddicoat, RV et al. Journal of Urban Health.
Epublished ahead of print.
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CONTINUING MEDICAL EDUCATION CREDIT

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for continuing
Medical Education through the joint sponsorship of Medical Education Collaborative, Inc. (MEC) and IDCR. MEC is accredited by the ACCME to
provide continuing medical education for physicians.
Medical Education Collaborative designates this educational activity for a maximum of 1.3 AMA PRA Category 1 Credit(s)™. Physicians should only
claim credit commensurate with the extent of their participation in the activity. Statements of credit will be mailed within 6 to 8 weeks following the
program.
Objectives:
The learner will be able to describe the prevalence of acquired HIV drug resistance.
The learner will become familiar with the concept of reduced viral fitness of resistant HIV virus
The learner will understand the design and results of the recent U.S. Centers for Disease Control and Prevention trial of interventions to reduce
HIV/STD risk behaviors among young men released from prison.
1.

2.

3.

Human Services for the initial treatment of HIV infected adolescents
and adults recommends that HIV genotype resistance testing
should be performed:
A. In chronically infected patients initiating HIV therapy
B. In patients with acute infection starting HIV therapy
C. When virologic failure develops during HIV therapy
D. All the above

All of the following statements regarding transmitted HIV drug resis
tance are true EXCEPT:
A. In studies of acutely and recently infected patients, transmitted
HIV drug resistance has been found in less than 5% of patients
B. Transmitted HIV drug resistance has increased since the mid1990s.
C. Resistance to the non-nucleoside reverse transcriptase
inhibitors (NNRTIs) is the most common HIV drug resistance
seen in recently infected patients.
D. None of the above
In the AIDS Clinical Trials Group (ACTG) study A5142 of treatment
naïve patients, at 96 weeks:
A. Almost half of those assigned efavirenz plus two nucleosides
who had genotype resistance testing results available had
NNRTI resistance detected
B. Resistance to lopinavir was not seen in those patients
assigned to this drug and who had genotype resistance testing
results available
C. The overwhelming majority of patients assigned to efavirenz or
lopinavir/ritonavir plus 2 nucleosides had HIV viral loads below
50 copies/mL/
D. All the above
Treatment guidelines issued by the US Department of Health

4.

In the CDC study of interventions to reduce HIV risk behaviors
among young men being released from prison at week 24 after
release:
A. Neither the enhance or the single-session intervention was
found to reduce risk behavior
B. Surprisingly, those assigned the single-session intervention
reported less risk behaviors than those receiving the enhanced
intervention
C. The enhanced intervention was found to reduce risk behaviors
of participants mostly with their participants main partner rather
than casual partners.
D. All the above

5.

Resistance to an HIV medication that develops during therapy
remains present in the body after the medication is discontinued
even though resistance testing may indicate otherwise
(TRUE or FALSE)?

In order to receive credit, participants must score at least a 70% on the post test and submit it along with the credit
application and evaluation form to the address/fax number indicated. Statements of credit will be mailed within 6-8 weeks
following the program.
Instructions:

• Applications for Credit will be accepted until
December 30, 2007.

• Late applications will not be accepted.
• Please anticipate 6-8 weeks to recieve your certificate.
Please print clearly as illegible applications will result in a delay.

Name:

_________________________________________________ Profession: __________________________________

License #: ___________________________________ State of License: __________________________________________
Address: ____________________________________________________________________________________________
City: ________________________ State: ________ Zip: ________________________ Telephone: ___________________
Please Check which credit you are requesting

___ ACCME or

___ Non Physicians

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------I certify that I participated in IDCR monograph - December 2006 Issue
Please fill in the number of actual hours that you attended this activity.
Date of participation: ______________________
Number of Hours (max. 1.3): ___________________
Signature: _________________________________________________

Please Submit Completed Application to:
Medical Education Collaborative
651 Corporate Circle, Suite 104, Golden CO 80401
Phone: 303-420-3252 FAX: 303-420-3259
For questions regarding the accreditation of this activity, please call
303-420-3252
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visit IDCR online at www.IDCRonline.org

COURSE EVALUATION
I. Please evaluate this educational activity by checking the appropriate box:
Activity Evaluation

Excellent

Very Good

Good

Fair

Faculty
Content
How well did this activity avoid commercial bias and present content that
was fair and balanced?
What is the likelihood you will
change the way you practice based
on what you learned in this activity?
Overall, how would you rate
this activity?

II. Course Objectives
Were the following overall course objectives met? At the conclusion of this presentation, are you able to:

•
•
•

The learner will be able to describe the prevalence of acquired HIV drug resistance.

YES

NO

SOMEWHAT

The learner will become familiar with the concept of reduced viral fitness of resistant HIV virus

YES
YES

NO
NO

SOMEWHAT
SOMEWHAT

The learner will understand the design and results of the recent U.S. Centers for Disease
Control and Prevention trial of interventions to reduce HIV/STD risk behaviors among young
men released from prison.

III. Additional Questions
a. Suggested topics and/or speakers you would like for future activities.

b. Additional Comments

Poor

